To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Bridgeport Hospital
Bridgeport, Connecticut, United States
Yale-New Haven Hospital
New Haven, Connecticut, United States
Time-to-cutaneous Re-epithelialization
Time frame: The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days
Time-to-mucosal Re-epithelialization
Time frame: The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days
Time-to-cessation of Epidermal Necrosis
Time frame: The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.